---
title: "Spero Therapeutics, Inc. (SPRO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SPRO.US.md"
symbol: "SPRO.US"
name: "Spero Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-06-19T10:56:10.853Z"
locales:
  - [en](https://longbridge.com/en/quote/SPRO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SPRO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SPRO.US.md)
---

# Spero Therapeutics, Inc. (SPRO.US)

## Company Overview

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [erotherapeutics.com](https://erotherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-19T04:30:13.000Z

**Overall: B (0.22)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 51 / 389 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 37.24% |  |
| Net Profit YoY | 121.84% |  |
| P/B Ratio | 2.49 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 132015404.04 |  |
| Revenue | 61186000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 35.12% | A |
| Profit Margin | 24.90% | A |
| Gross Margin | -1027.52% | E |
| Revenue YoY | 37.24% | A |
| Net Profit YoY | 121.84% | A |
| Total Assets YoY | -24.05% | E |
| Net Assets YoY | 56.54% | A |
| Cash Flow Margin | 47.54% | C |
| OCF YoY | 37.24% | A |
| Turnover | 0.89 | B |
| Gearing Ratio | 10.31% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Spero Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "37.24%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "121.84%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.49",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "132015404.04",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "61186000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "35.12%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "24.90%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "-1027.52%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "37.24%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "121.84%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-24.05%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "56.54%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "47.54%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "37.24%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.89",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "10.31%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 8.67 | 23/389 | 18.03 | 16.41 | 10.49 |
| PB | 2.49 | 220/389 | 4.95 | 4.05 | 3.10 |
| PS (TTM) | 2.16 | 54/389 | 3.29 | 2.83 | 2.32 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-05T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.28 |
| Highest Target | 4.00 |
| Lowest Target | 4.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SPRO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SPRO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SPRO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SPRO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**